Results Transparency Scoreboard

EU Clinical Trials Regulation 536/2014, Article 37(4): summary of results due within 12 months from end of trial in all Member States concerned (6 months for paediatric trials).

3,309 ended trials 906 results posted 803 overdue 1,600 in grace period 27.4% global compliance

As of 5 June 2026 · CTIS public registry snapshot · 2,123 trials excluded (no end date reported)

3,309 Ended trials
incl. 323 paediatric
906 Results posted
803 Overdue
past 12m (6m paediatric)
1,600 In grace period
deadline not yet elapsed
27.4% Global compliance

Compliance by year of trial end (2021 onwards):

2022: 83.3% (6) 2023: 74.4% (133) 2024: 42.5% (669) 2025: 28.1% (1,789) 2026: 2.3% (711)

Recent years (2025–2026) include trials still within the 12-month grace period (6 months for paediatric) — those are not counted as overdue. Years 2020 and earlier are excluded: they fall under Directive 2001/20/EC / Commission Guidelines 2012/C 302/03 and are tracked in EudraCT/EUCTR, not CTIS.

Regulatory context

Under Article 37(4) of Regulation (EU) No 536/2014, sponsors must submit a summary of clinical trial results to the EU database within 12 months of the end of the trial in all Member States concerned (6 months for paediatric trials), unless scientific reasons justifying delay are pre-specified in the protocol.

This scoreboard tracks compliance based on publicly available CTIS data for trials authorised under CTR (post-31 January 2022). Legacy trials under Directive 2001/20/EC and the 2012 Commission Guidelines are tracked separately via EudraCT/EUCTR.

How we calculate these numbers (sponsor scoreboard methodology)

Population

  • Status: trials with ctPublicStatusCode IN ('5', '8') — i.e. "Ended" (5) or "Ended early/Halted-final" (8). Active, suspended, halted-pending and pre-approval statuses are excluded.
  • End date required: trials without endDateEU are excluded from the entire scoreboard (2,123 trials affected). Without a verified end date, Article 37(4) deadline cannot be evaluated.
  • Sponsor attribution: each trial is attributed to its primary sponsor (trial_sponsors.is_primary = 1). A small subset of trials (~167) declares two or more co-primary sponsors — those trials are attributed to each co-sponsor (every co-primary takes responsibility for results).
  • Sponsor deduplication: legal-form variants of the same organisation ("Novartis Pharma AG / GmbH / SAS") are collapsed via the canonical_sponsor_map table into a single row.
  • Visibility filter: only sponsors with ≥ 2 ended trials are shown (singletons are excluded — too few data points for a meaningful compliance rate).

Bucket definitions

  • Ended trials — distinct count of qualifying trials per sponsor (COUNT DISTINCT trial_id).
  • Results posted — trials where trial_results.summaryResults is non-null / non-empty (Annex IV summary submitted).
  • Layperson summary — same field check on trial_results.laypersonResults (Annex V).
  • Overdue — past the Article 37(4) deadline without posted results. Deadline = endDateEU + 12 months for adult trials, + 6 months for paediatric trials. Paediatric is determined from trial_details_information.ageRanges containing "1" (in utero) or "2" (0–17 years).
  • In grace period — ended on or before today, but deadline has not yet elapsed. Not counted as non-compliant.
  • Compliance % — results_posted / ended × 100, rounded to one decimal place.

Sponsor type

Academic vs. Commercial is a heuristic on the organisation name, not a CTIS field. A sponsor is tagged Academic if its name matches: University, Universit[eéà], Hospital, H[oô]pital, Institut, Foundation, Fondation, NHS, Academic, Research Centre, Centro, Klinik, Assistance, Charit[eé], APHP. Otherwise tagged Commercial. Edge cases (e.g. consortia, government bodies) may be misclassified.

Known caveats

  • The scientific-justification exception under Art. 37(4) is not exposed in public CTIS fields. Sponsors invoking it for legitimate scientific reasons will appear here as overdue. This is a known limitation of any CTIS-only audit.
  • Sums across sponsor rows can exceed the global totals because trials with co-primary sponsors are counted under each. The 5-tile global stats use COUNT DISTINCT trial_id and therefore count each trial exactly once.
  • This scoreboard only covers trials in CTIS (CTR-authorised, post-31 January 2022; fully migrated 31 January 2025). Pre-CTR trials reporting under Directive 2001/20/EC and the 2012 Commission Guidelines are tracked separately in EudraCT/EUCTR.
Sort by
# Sponsor Type Ended trials Results posted Layperson summary Compliance Overdue In grace
1 Merck Sharp & Dohme LLC Commercial 124 32 33
25.8%
32 62
2 Boehringer Ingelheim International GmbH Commercial 97 20 20
20.6%
42 37
3 AstraZeneca AB Commercial 75 18 18
24%
20 38
4 F. Hoffmann-La Roche AG Commercial 65 21 15
32.3%
21 28
5 Pfizer Inc. Commercial 62 12 12
19.4%
24 27
6 Janssen - Cilag International Commercial 56 15 14
26.8%
20 21
7 Novartis Pharma AG Commercial 55 20 19
36.4%
10 25
8 Novo Nordisk A/S Commercial 46 11 11
23.9%
10 25
9 Eli Lilly & Co. Commercial 40 12 12
30%
6 23
10 Sanofi-Aventis Recherche & Developpement Commercial 36 9 9
25%
10 18
11 AbbVie Deutschland GmbH & Co. KG Commercial 35 16 16
45.7%
3 17
12 Bayer AG Commercial 35 11 11
31.4%
12 14
13 Assistance Publique Hopitaux De Paris Academic 31 2 0
6.5%
8 22
14 Glaxosmithkline Research & Development Limited Commercial 31 10 10
32.3%
7 14
15 Sun Pharmaceutical Industries Limited Commercial 29 3 3
10.3%
11 15
16 Bristol Myers Squibb International Corporation Commercial 28 19 18
67.9%
4 7
17 Takeda Development Center Americas Inc. Commercial 26 13 13
50%
2 11
18 Centre Hospitalier Universitaire De Nantes Academic 24 5 5
20.8%
8 13
19 Laboratorios Normon S.A. Commercial 23 9 9
39.1%
9 5
20 Incyte Corp. Commercial 22 5 5
22.7%
3 14
21 Celgene Corp. Commercial 21 5 5
23.8%
13 6
22 Amgen Inc. Commercial 20 8 6
40%
2 10
23 Genentech Inc. Commercial 19 3 4
15.8%
3 13
24 Regeneron Pharmaceuticals Inc. Commercial 19 7 7
36.8%
3 9
25 UZ Leuven Commercial 19 2 3
10.5%
1 16
26 CCDRD Cooperative Clinical Drug Research and Development AG Commercial 18 2 2
11.1%
8 8
27 Bluepharma Industria Farmaceutica S.A. Commercial 17 4 4
23.5%
9 4
28 Chiesi Farmaceutici S.p.A. Commercial 17 2 2
11.8%
7 9
29 Amsterdam UMC Stichting Commercial 16 3 3
18.8%
4 9
30 GlaxoSmithKline Biologicals Commercial 15 10 10
66.7%
2 5
31 Rigshospitalet Academic 15 0 0
0%
7 10
32 Bristol-Myers Squibb Services Unlimited Company Commercial 14 4 4
28.6%
4 8
33 Laboratorios Alter S.A. Commercial 13 2 2
15.4%
7 4
34 Universitair Medisch Centrum Groningen Commercial 13 1 1
7.7%
4 8
35 Argenx Commercial 12 3 3
25%
1 8
36 Genmab A/S Commercial 12 7 7
58.3%
— 6
37 Institut De Recherches Internationales Servier IRIS Academic 12 1 1
8.3%
5 7
38 Merck Healthcare KGaA Commercial 12 3 3
25%
5 4
39 UCB Biopharma Commercial 12 5 5
41.7%
1 6
40 Adamed Pharma S.A. Commercial 11 2 2
18.2%
5 4
41 Bioprojet Pharma Commercial 11 4 4
36.4%
5 3
42 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Commercial 11 1 1
9.1%
4 6
43 Gilead Sciences Inc. Commercial 11 6 6
54.5%
2 4
44 Laboratorios Cinfa S.A. Commercial 11 2 2
18.2%
3 6
45 Laboratorios Leon Farma S.A. Commercial 11 2 2
18.2%
4 5
46 Oslo University Hospital HF Academic 11 7 5
63.6%
1 5
47 Seagen Inc. Commercial 11 2 2
18.2%
2 7
48 Universitair Medisch Centrum Utrecht Commercial 11 3 2
27.3%
1 7
49 Radboud universitair medisch centrum Stichting Commercial 10 1 1
10%
3 6
50 Centre for Human Drug Research Commercial 9 0 0
0%
6 3
51 Daiichi Sankyo Inc. Commercial 9 1 1
11.1%
— 9
52 Institut Gustave Roussy Academic 9 2 0
22.2%
6 3
53 Medica Scientia Innovation Research S.L. Commercial 9 5 5
55.6%
— 4
54 Medical University Of Vienna Academic 9 4 3
44.4%
— 5
55 Odense University Hospital Academic 9 1 1
11.1%
— 8
56 Universitaetsklinikum Heidelberg AöR Academic 9 2 2
22.2%
2 5
57 Alexion Pharmaceuticals Inc. Commercial 8 4 4
50%
2 2
58 Bayer Consumer Care AG Commercial 8 5 5
62.5%
3 1
59 Charite Universitaetsmedizin Berlin KöR Academic 8 3 3
37.5%
1 4
60 CSL Behring LLC Commercial 8 5 5
62.5%
1 2
61 Kite Pharma Inc. Commercial 8 4 4
50%
2 2
62 Taiho Oncology Inc. Commercial 8 3 3
37.5%
3 2
63 Amsterdam UMC Commercial 7 0 0
0%
1 6
64 Astellas Pharma Global Development Inc. Commercial 7 5 5
71.4%
— 2
65 Centre Leon Berard Commercial 7 1 0
14.3%
— 7
66 Dr. Falk Pharma GmbH Commercial 7 0 0
0%
4 4
67 Farmalider S.A. Commercial 7 1 1
14.3%
4 2
68 Immunovant Sciences GmbH Commercial 7 0 0
0%
— 7
69 Leids Universitair Medisch Centrum (LUMC) Commercial 7 1 1
14.3%
— 6
70 Medical University Of Graz Academic 7 1 1
14.3%
— 6
71 Moderna Inc. Commercial 7 2 1
28.6%
3 2
72 Region Midtjylland Commercial 7 2 2
28.6%
— 5
73 Stichting Radboud University Medical Center Academic 7 2 2
28.6%
2 3
74 Tarchominskie Zaklady Farmaceutyczne Polfa S.A. Commercial 7 1 1
14.3%
1 5
75 Zealand Pharma A/S Commercial 7 1 1
14.3%
1 5
76 Aarhus Universitet Academic 6 3 4
50%
— 3
77 Antibiotice S.A. Commercial 6 1 0
16.7%
5 —
78 Arrowhead Pharmaceuticals Inc. Commercial 6 2 2
33.3%
— 4
79 Beigene Ltd. Commercial 6 3 3
50%
— 3
80 Faes Farma S.A. Commercial 6 0 0
0%
3 3
81 Fondation Franc.Cancerologie Digestive Academic 6 4 4
66.7%
— 2
82 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 6 2 2
33.3%
— 4
83 Hospices Civils De Lyon Commercial 6 0 0
0%
4 2
84 Inmunotek S.L. Commercial 6 5 5
83.3%
— 1
85 Ipsen Pharma Commercial 6 1 1
16.7%
4 1
86 Karolinska University Hospital Academic 6 2 2
33.3%
2 2
87 Leiden University Medical Center Academic 6 4 3
66.7%
1 1
88 Medical University Of Gdansk Academic 6 1 1
16.7%
— 5
89 Ospedale San Raffaele S.r.l. Commercial 6 1 1
16.7%
1 4
90 Otsuka Pharmaceutical Development & Commercialization Inc. Commercial 6 4 4
66.7%
— 3
91 Pharvaris Netherlands B.V. Commercial 6 1 1
16.7%
4 1
92 Region Hovedstaden Commercial 6 1 0
16.7%
— 5
93 Solti Group Commercial 6 3 3
50%
1 2
94 Tecnimede-Sociedade Tecnico-Medicinal S.A. Commercial 6 1 1
16.7%
3 2
95 Teikoku Seiyaku Co. Ltd. Commercial 6 0 0
0%
4 3
96 Teva Branded Pharmaceutical Products R&D LLC Commercial 6 1 1
16.7%
2 3
97 Abivax Commercial 5 0 0
0%
3 2
98 Antwerp University Hospital Academic 5 1 1
20%
2 2
99 BioNTech SE Commercial 5 0 0
0%
1 4
100 Centre hospitalier universitaire de Liege Academic 5 1 1
20%
— 4
101 Centre Hospitalier Universitaire De Saint Etienne Academic 5 0 0
0%
1 4
102 Chemo Research S.L. Commercial 5 2 2
40%
— 3
103 Crinetics Pharmaceuticals Inc. Commercial 5 0 0
0%
1 4
104 Dompe' Farmaceutici S.p.A. Commercial 5 5 5
100%
— —
105 Gentofte Hospital Academic 5 1 1
20%
— 5
106 H. Lundbeck A/S Commercial 5 2 2
40%
1 2
107 Horizon Therapeutics Ireland Designated Activity Company Commercial 5 4 3
80%
— 1
108 Insmed Inc. Commercial 5 1 1
20%
— 4
109 Institut Bergonie Academic 5 2 2
40%
— 4
110 Intercept Pharmaceuticals Inc. Commercial 5 1 1
20%
— 4
111 Ionis Pharmaceuticals Inc. Commercial 5 2 2
40%
1 2
112 Klinikum der Universitaet Muenchen AöR Academic 5 1 1
20%
— 4
113 Laboratorios Lesvi S.L. Commercial 5 4 4
80%
— 1
114 Leo Pharma A/S Commercial 5 1 1
20%
— 4
115 MoonLake Immunotherapeutics AG Commercial 5 0 0
0%
1 4
116 Myokardia Inc. Commercial 5 4 4
80%
1 1
117 Orion Corporation Commercial 5 2 2
40%
— 3
118 Pharma Mar S.A. Commercial 5 0 0
0%
1 4
119 PTC Therapeutics Inc. Commercial 5 3 3
60%
2 —
120 Sanofi-Aventis Research & Development Commercial 5 1 1
20%
2 2
121 Universitaetsklinikum Tuebingen AöR Academic 5 1 1
20%
— 4
122 Vaestra Goetalandsregionen Commercial 5 1 1
20%
2 3
123 Vertex Pharmaceuticals Inc. Commercial 5 3 3
60%
— 2
124 Viiv Healthcare UK Limited Commercial 5 4 4
80%
— 2
125 Aalborg University Hospital Academic 4 1 1
25%
— 3
126 Academisch Ziekenhuis Leiden Commercial 4 1 1
25%
1 2
127 Arvinas Operations Inc. Commercial 4 0 0
0%
1 3
128 BeOne Medicines AG Commercial 4 0 0
0%
— 4
129 Bial Portela & Ca S.A. Commercial 4 0 0
0%
3 1
130 Biogen Idec Research Limited Commercial 4 2 2
50%
— 2
131 Biohaven Therapeutics Ltd. Commercial 4 1 1
25%
1 2
132 Cannaxan GmbH Commercial 4 0 0
0%
— 4
133 Celon Pharma S.A. Commercial 4 0 0
0%
2 2
134 Cepha s.r.o. Commercial 4 0 0
0%
4 —
135 Ferring Pharmaceuticals A/S Commercial 4 1 1
25%
1 2
136 Fundacio De Recerca Clinic Barcelona-Institut D’Investigacio… Academic 4 0 0
0%
1 3
137 Fundacion Publica Andaluza Para La Gestion De La Investigaci… Commercial 4 2 2
50%
— 2
138 Galapagos Commercial 4 1 1
25%
1 2
139 GE Healthcare Limited Commercial 4 0 0
0%
2 2
140 Genzyme Corp. Commercial 4 0 0
0%
1 3
141 Groupe Oncologie Radiotherapie Tete Cou Commercial 4 1 1
25%
1 2
142 Hipra Scientific S.L. Commercial 4 4 4
100%
— 1
143 Hutchmed Ltd. Commercial 4 0 0
0%
4 —
144 Idorsia Pharmaceuticals Ltd. Commercial 4 2 2
50%
1 2
145 Institut Curie Academic 4 4 3
100%
— 1
146 Institute Of Tropical Medicine Academic 4 2 2
50%
— 3
147 Iovance Biotherapeutics Inc. Commercial 4 0 0
0%
1 3
148 Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Pan… Commercial 4 1 1
25%
2 2
149 Neurocrine Biosciences Inc. Commercial 4 2 2
50%
1 1
150 Parc De Salut Mar Commercial 4 0 0
0%
3 1
151 Pharmaplot P.C. Commercial 4 0 0
0%
4 —
152 Pharming Technologies B.V. Commercial 4 1 1
25%
2 1
153 Philogen S.p.A. Commercial 4 0 0
0%
1 3
154 Praxis Precision Medicines Inc. Commercial 4 1 1
25%
1 2
155 Prelude Therapeutics Inc. Commercial 4 0 0
0%
— 4
156 Quralis Corp. Commercial 4 0 0
0%
3 1
157 Region Uppsala Commercial 4 1 1
25%
— 3
158 Replimune Group Inc. Commercial 4 0 0
0%
— 4
159 ROXALL Medizin GmbH Commercial 4 0 0
0%
3 2
160 Sparrow Pharmaceuticals Inc. Commercial 4 0 0
0%
4 1
161 Swedish Orphan Biovitrum AB (publ) Commercial 4 3 3
75%
— 1
162 Technische Universitat Dresden Commercial 4 2 2
50%
— 2
163 Unicancer Commercial 4 0 0
0%
2 2
164 University College Dublin Academic 4 2 2
50%
2 —
165 Vianex S.A. Commercial 4 0 0
0%
1 3
166 Viridian Therapeutics Inc. Commercial 4 2 2
50%
— 2
167 Zaklady Farmaceutyczne Polpharma S.A. Commercial 4 0 0
0%
2 2
168 Aarhus University Hospital Academic 3 2 2
66.7%
— 1
169 Acadia Pharmaceuticals Inc. Commercial 3 2 2
66.7%
1 —
170 Acceleron Pharma Inc. Commercial 3 2 2
66.7%
— 1
171 Acelyrin Inc. Commercial 3 3 3
100%
— —
172 Achieve Life Sciences Inc. Commercial 3 3 3
100%
— —
173 Actelion Pharmaceuticals Ltd. Commercial 3 1 1
33.3%
1 1
174 ADC Therapeutics S.A. Commercial 3 1 1
33.3%
2 —
175 Agomab Spain S.L. Commercial 3 1 1
33.3%
1 1
176 Alector LLC Commercial 3 3 3
100%
— —
177 Almirall S.A. Commercial 3 2 2
66.7%
— 1
178 Alnylam Pharmaceuticals Inc. Commercial 3 1 1
33.3%
1 3
179 Alx Oncology Inc. Commercial 3 1 1
33.3%
— 2
180 Anaptysbio Inc. Commercial 3 1 1
33.3%
2 1
181 Apellis Pharmaceuticals Inc. Commercial 3 1 1
33.3%
— 2
182 Arcus Biosciences Inc. Commercial 3 0 0
0%
1 2
183 Areteia Therapeutics Inc. Commercial 3 0 0
0%
2 1
184 Blueprint Medicines Corp. Commercial 3 2 2
66.7%
— 1
185 Cardurion Pharmaceuticals Inc. Commercial 3 1 1
33.3%
— 2
186 Centre Hospitalier Regional Et Universitaire De Brest Academic 3 0 0
0%
— 3
187 Centre Hospitalier Regional Universitaire De Tours Academic 3 2 2
66.7%
— 1
188 Centre Hospitalier Universitaire Grenoble Alpes Academic 3 0 0
0%
3 —
189 Centre Hospitalier Universitaire Rouen Academic 3 0 0
0%
3 1
190 CHRU De Nancy Commercial 3 1 1
33.3%
— 2
191 Clinuvel Europe Limited Commercial 3 3 3
100%
— —
192 Curateq Biologics Private Limited Commercial 3 0 0
0%
— 3
193 Debiopharm International S.A. Commercial 3 0 0
0%
— 3
194 Deciphera Pharmaceuticals Inc. Commercial 3 0 0
0%
— 3
195 Dermax Commercial 3 1 1
33.3%
2 —
196 DICE Therapeutics Inc. Commercial 3 2 2
66.7%
— 1
197 Dragonfly Therapeutics Inc. Commercial 3 0 0
0%
— 3
198 Fondation A De Rothschild Academic 3 1 1
33.3%
— 2
199 Fulcrum Therapeutics Inc. Commercial 3 3 3
100%
— —
200 Fundacion Grupo Espanol De Investigacion En Cancer De Mama Commercial 3 1 1
33.3%
— 2
201 Fundacion Seimc Gesida Commercial 3 1 2
33.3%
1 2
202 Goethe University Frankfurt Academic 3 1 1
33.3%
— 2
203 H e x a l AG Commercial 3 0 0
0%
— 3
204 Hansa Biopharma AB Commercial 3 1 1
33.3%
— 2
205 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichtin… Commercial 3 0 0
0%
— 3
206 Herlev Hospital Academic 3 3 3
100%
— —
207 Hifibio Inc. Commercial 3 0 0
0%
— 3
208 Hospital General Universitario Dr. Balmis Academic 3 2 0
66.7%
1 —
209 HUS-Yhtymae Commercial 3 0 0
0%
2 1
210 IGM Biosciences Inc. Commercial 3 0 0
0%
3 —
211 InflaRx GmbH Commercial 3 1 1
33.3%
1 1
212 Institut De Cancerologie De L Ouest Academic 3 0 0
0%
— 3
213 Instytut Pomnik Centrum Zdrowia Dziecka Commercial 3 0 0
0%
3 —
214 IO Biotech ApS Commercial 3 1 1
33.3%
— 2
215 iTeos Belgium Commercial 3 2 2
66.7%
— 1
216 K-Group Beta Inc. Commercial 3 1 1
33.3%
— 2
217 KRKA tovarna zdravil d.d. Novo mesto Commercial 3 1 1
33.3%
— 2
218 Les Hopitaux Universitaires De Strasbourg Commercial 3 0 0
0%
2 1
219 Martin-Luther-Universitaet Halle-Wittenberg Commercial 3 1 1
33.3%
— 2
220 Masarykova Univerzita Commercial 3 0 0
0%
2 1
221 Medical University Of Warsaw Academic 3 0 0
0%
1 2
222 Noucor Health S.A. Commercial 3 0 0
0%
1 2
223 Novadip Biosciences Commercial 3 0 0
0%
1 2
224 Octapharma Pharmazeutika Produktionsgesellschaft mbH Commercial 3 1 1
33.3%
— 2
225 Oncopole Claudius Regaud Commercial 3 2 1
66.7%
— 1
226 Region Skane Commercial 3 0 0
0%
2 1
227 Royal College Of Surgeons In Ireland Commercial 3 2 2
66.7%
— 1
228 Sage Therapeutics Inc. Commercial 3 1 1
33.3%
— 2
229 Sarepta Therapeutics Inc. Commercial 3 2 2
66.7%
1 —
230 Sutro Biopharma Inc. Commercial 3 0 0
0%
2 1
231 Syros Pharmaceuticals Inc. Commercial 3 0 0
0%
3 —
232 TargED Biopharmaceuticals B.V. Commercial 3 1 1
33.3%
1 1
233 Universitaet Muenster Commercial 3 0 0
0%
1 2
234 Universitaetsklinikum Essen AöR Academic 3 0 0
0%
— 3
235 Universitaetsklinikum Schleswig-Holstein AöR Academic 3 0 0
0%
— 3
236 Universitaetsmedizin Goettingen Commercial 3 0 0
0%
— 3
237 Universitair Ziekenhuis Gent Commercial 3 0 0
0%
1 2
238 University Hospital Maastricht Academic 3 3 3
100%
— —
239 University Medical Center Hamburg-Eppendorf Academic 3 1 1
33.3%
— 2
240 University Medical Center Utrecht Academic 3 2 2
66.7%
— 1
241 University Of Cologne Academic 3 3 3
100%
— —
242 Achilles Therapeutics UK Limited Commercial 2 2 2
100%
— —
243 Aco Hud Nordic AB Commercial 2 1 1
50%
1 —
244 Aerovate Therapeutics Inc. Commercial 2 2 2
100%
— —
245 Affimed GmbH Commercial 2 0 2
0%
— 4
246 AiCuris Anti-infective Cures AG Commercial 2 0 0
0%
1 1
247 Akamis Bio Limited Commercial 2 0 0
0%
2 —
248 Alentis Therapeutics AG Commercial 2 1 1
50%
1 —
249 Alfasigma S.p.A. Commercial 2 1 1
50%
1 —
250 Alkaloid AD Skopje Commercial 2 0 0
0%
2 —
251 Alkermes Inc. Commercial 2 0 0
0%
— 2
252 Allogene Therapeutics Inc. Commercial 2 1 1
50%
1 —
253 Alter Farmacia S.A. Commercial 2 1 1
50%
1 —
254 Alumis Inc. Commercial 2 0 0
0%
— 2
255 Alvotech Swiss AG Commercial 2 1 1
50%
— 1
256 AM-Pharma B.V. Commercial 2 2 2
100%
— —
257 Amylyx Pharmaceuticals EMEA B.V. Commercial 2 0 0
0%
2 —
258 Amylyx Pharmaceuticals Inc. Commercial 2 0 0
0%
1 1
259 Amzell B.V. Commercial 2 1 1
50%
1 —
260 Anthos Therapeutics Inc. Commercial 2 0 0
0%
— 2
261 Apcintex Limited Commercial 2 2 2
100%
— —
262 Arbutus Biopharma Inc. Commercial 2 0 0
0%
1 1
263 Ascendis Pharma Oncology Division A/S Commercial 2 1 1
50%
— 1
264 Association International Extranodal Lymphoma Study Group (I… Commercial 2 0 0
0%
— 2
265 Atea Pharmaceuticals Inc. Commercial 2 3 3
150%
— —
266 Azafaros B.V. Commercial 2 1 1
50%
1 —
267 Baxalta Innovations GmbH Commercial 2 0 0
0%
1 1
268 Bellvitge University Hospital Academic 2 0 0
0%
— 2
269 Biocodex Commercial 2 0 0
0%
1 1
270 BioInvent International AB Commercial 2 0 0
0%
— 2
271 Biomarin Pharmaceutical Inc. Commercial 2 0 0
0%
1 1
272 Bispebjerg Hospital Academic 2 0 0
0%
— 2
273 Bolt Biotherapeutics Inc. Commercial 2 2 2
100%
— —
274 Breye Therapeutics ApS Commercial 2 0 0
0%
1 1
275 Calliditas Therapeutics Suisse S.A. Commercial 2 2 2
100%
— —
276 Camurus AB Commercial 2 1 1
50%
— 1
277 Cancer Trials Ireland Commercial 2 0 0
0%
— 2
278 Cardiol Therapeutics Inc. Commercial 2 1 1
50%
1 —
279 Carrick Therapeutics Limited Commercial 2 0 0
0%
— 2
280 Cassiopea S.p.A. Commercial 2 0 0
0%
1 2
281 Celgene International II SARL Commercial 2 2 2
100%
— —
282 Cell2cure ApS Commercial 2 0 0
0%
— 2
283 Cellaïon SA Commercial 2 2 2
100%
— —
284 Celldex Therapeutics Inc. Commercial 2 0 0
0%
— 2
285 Celltrion Inc. Commercial 2 0 0
0%
— 2
286 Centre Francois Baclesse Commercial 2 2 2
100%
— —
287 Centre Hospitalier Departemental Vendee Academic 2 0 0
0%
— 2
288 Centre Hospitalier Regional De Marseille Academic 2 0 0
0%
1 1
289 Centre Hospitalier Universitaire Amiens Picardie Academic 2 0 0
0%
1 1
290 Centre Hospitalier Universitaire D'Angers Academic 2 0 0
0%
— 2
291 Centre Hospitalier Universitaire De Bordeaux Academic 2 0 0
0%
1 1
292 Centre Hospitalier Universitaire De Dijon Academic 2 0 0
0%
2 —
293 Cerevel Therapeutics LLC Commercial 2 1 1
50%
— 1
294 CHU Gabriel-Montpied Commercial 2 0 0
0%
— 2
295 Cinclus Pharma Holding AB (publ) Commercial 2 0 0
0%
— 2
296 Clinica Universidad De Navarra Commercial 2 1 1
50%
— 1
297 Cliniques Universitaires Saint-Luc Commercial 2 1 1
50%
— 1
298 Consorcio Centro De Investigacion Biomedica En Red Academic 2 1 1
50%
— 1
299 Curevac AG Commercial 2 0 0
0%
— 2
300 Curis Inc. Commercial 2 0 0
0%
2 —
301 Cyclacel Limited Commercial 2 0 0
0%
2 —
302 Cytokinetics Inc. Commercial 2 1 1
50%
— 1
303 Delix Therapeutics Inc. Commercial 2 0 0
0%
1 2
304 Diamyd Medical AB Commercial 2 0 0
0%
— 2
305 Diater Laboratorio De Diagnostico Y Aplicaciones Terapeutica… Commercial 2 1 1
50%
— 1
306 Dicot AB Commercial 2 0 0
0%
2 1
307 Direction Centrale Du Service De Sante Des Armees Commercial 2 0 0
0%
2 —
308 Dr. Willmar Schwabe GmbH & Co. KG Commercial 2 1 1
50%
1 —
309 Eip Pharma Inc. Commercial 2 0 0
0%
1 1
310 Eisai Limited Commercial 2 1 1
50%
1 —
311 Empros Pharma AB Commercial 2 2 2
100%
— —
312 ENYO Pharma Commercial 2 0 0
0%
— 2
313 Epiendo Pharmaceuticals ehf. Commercial 2 0 0
0%
2 1
314 Epizyme Inc. Commercial 2 0 0
0%
1 1
315 Eradivir Inc. Commercial 2 1 1
50%
— 1
316 Esbjerg Og Grindsted Sygehus Commercial 2 0 0
0%
1 1
317 Escient Pharmaceuticals Inc. Commercial 2 1 1
50%
1 —
318 ETOP IBCSG Partners Foundation Academic 2 1 1
50%
— 1
319 Eurofins Optimed Commercial 2 0 0
0%
2 —
320 European Organisation For Research And Treatment Of Cancer Commercial 2 1 1
50%
— 1
321 Eva Pharma For Pharmaceuticals And Medical Appliances SAE Commercial 2 0 0
0%
2 —
322 Finnish Institute For Health And Welfare Academic 2 0 0
0%
— 2
323 Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Commercial 2 0 0
0%
1 1
324 Fondazione Italiana Linfomi Ets Commercial 2 0 0
0%
— 2
325 Friedrich-Schiller-Universitaet Jena Commercial 2 0 0
0%
2 1
326 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIB… Academic 2 1 1
50%
— 1
327 Fundacio Institut De Recerca De L'Hospital De La Santa Creu … Academic 2 0 0
0%
1 1
328 Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infec… Commercial 2 0 0
0%
— 2
329 Fundacion GECP Commercial 2 1 1
50%
— 1
330 Fundacion PETHEMA Commercial 2 2 2
100%
— 1
331 Galecto Biotech AB Commercial 2 2 2
100%
— —
332 Gan & Lee Pharmaceuticals USA Corp. Commercial 2 0 0
0%
— 2
333 Gebro Pharma GmbH Commercial 2 0 0
0%
1 1
334 Genetic S.p.A. Commercial 2 1 1
50%
— 1
335 Groupe Francophone Des Myelodysplasies Commercial 2 2 2
100%
— —
336 Groupement Des Hopitaux De L'Institut Catholique De Lille Academic 2 1 1
50%
— 1
337 Gruenenthal GmbH Commercial 2 1 1
50%
— 1
338 Grupo Espanol De Investigacion En Cancer De Ovario Commercial 2 1 1
50%
— 1
339 Haleon CH SARL Commercial 2 1 1
50%
— 1
340 Harmony Biosciences Management Inc. Commercial 2 1 1
50%
1 —
341 Helse Bergen HF Commercial 2 1 1
50%
— 1
342 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Zieke… Commercial 2 0 0
0%
— 2
343 Hospital Clinico San Carlos Academic 2 1 1
50%
— 1
344 Hvidovre Hospital Academic 2 1 1
50%
1 —
345 Immunic AG Commercial 2 0 0
0%
— 2
346 Innate Pharma Commercial 2 0 0
0%
— 2
347 Innovative Molecules GmbH Commercial 2 0 0
0%
1 1
348 Institut fuer Klinische Krebsforschung IKF GmbH Academic 2 0 0
0%
— 2
349 Institut National De La Sante Et De La Recherche Medicale Academic 2 0 0
0%
— 2
350 Institut Paoli Calmettes Academic 2 0 0
0%
1 1
351 Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Academic 2 1 1
50%
— 1
352 Instituto Oncologico Dr. Rosell S.L. Academic 2 0 0
0%
— 2
353 Integrative Research Laboratories Sweden AB Commercial 2 0 0
0%
2 —
354 Intellia Therapeutics Inc. Commercial 2 1 1
50%
1 —
355 Intergroupe Francophone De Cancerologie Thoracique Commercial 2 0 0
0%
— 2
356 Intra-Cellular Therapies Inc. Commercial 2 0 0
0%
— 2
357 Istituto Di Ricerche Farmacologiche Mario Negri Commercial 2 1 1
50%
— 1
358 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRS… Commercial 2 0 0
0%
— 2
359 Itb-Med AB Commercial 2 1 1
50%
— 1
360 Janssen Vaccines & Prevention B.V. Commercial 2 1 1
50%
— 1
361 Jasper Therapeutics Inc. Commercial 2 0 0
0%
1 1
362 Kalvista Pharmaceuticals Limited Commercial 2 0 0
0%
— 2
363 Karolinska Institutet Academic 2 0 0
0%
1 1
364 Karuna Therapeutics Inc. Commercial 2 1 1
50%
— 1
365 Kowa Research Institute Inc. Academic 2 0 0
0%
— 2
366 LAVA Therapeutics N.V. Commercial 2 1 1
50%
— 1
367 Leap Therapeutics Inc. Commercial 2 2 2
100%
— —
368 LiteVax B.V. Commercial 2 1 1
50%
1 —
369 LYSARC Commercial 2 1 1
50%
— 1
370 Mabxience Research S.L. Commercial 2 0 0
0%
1 1
371 Macrogenics Inc. Commercial 2 1 1
50%
— 1
372 Marinus Pharmaceuticals Inc. Commercial 2 1 1
50%
2 —
373 Mc2 Therapeutics Limited Commercial 2 2 2
100%
— —
374 Medibiofarma S.L. Commercial 2 3 3
150%
— —
375 Medical University Of Bialystok Academic 2 0 0
0%
— 2
376 Meiji Seika Pharma Co. Ltd. Commercial 2 1 1
50%
— 1
377 Merz Therapeutics GmbH Commercial 2 1 1
50%
— 1
378 Mundipharma Research Limited Commercial 2 2 2
100%
— 1
379 Mural Oncology Inc. Commercial 2 2 2
100%
— —
380 Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im … Commercial 2 0 0
0%
— 2
381 Nerviano Medical Sciences S.r.l. Commercial 2 2 2
100%
— 1
382 NMD Pharma A/S Commercial 2 0 0
0%
— 2
383 Noema Pharma AG Commercial 2 1 1
50%
— 1
384 Nordsjaellands Hospital Academic 2 0 0
0%
1 1
385 Ntc S.r.l. Commercial 2 0 0
0%
1 1
386 Oculis Operations S.a.r.l. Commercial 2 0 0
0%
2 —
387 Oncoinvent ASA Commercial 2 0 0
0%
1 1
388 Opthea Limited Commercial 2 2 2
100%
— —
389 Orchard Therapeutics (Europe) Limited Commercial 2 1 1
50%
— 1
390 Osivax Commercial 2 0 0
0%
1 1
391 Ospedale Pediatrico Bambino Gesu Commercial 2 1 1
50%
— 1
392 Otsuka Pharmaceutical Development And Commercialization Inc. Commercial 2 0 0
0%
— 2
393 Pathalys Pharma Inc. Commercial 2 0 0
0%
— 2
394 Phaxiam Therapeutics Commercial 2 0 0
0%
2 —
395 Pirkanmaan hyvinvointialue Commercial 2 1 1
50%
— 1
396 Principia Biopharma Inc. Commercial 2 0 0
0%
1 1
397 Prometheus Biosciences Inc. Commercial 2 0 0
0%
— 2
398 Quince Therapeutics S.p.A. Commercial 2 2 2
100%
— —
399 Recordati AG Commercial 2 0 0
0%
1 1
400 Repare Therapeutics USA Inc. Commercial 2 0 0
0%
2 —
401 Respirent Pharmaceuticals Co. Ltd. Commercial 2 0 0
0%
2 —
402 Rheinische Friedrich-Wilhelms-Universitaet Bonn Commercial 2 0 0
0%
— 2
403 River 2 Renal Corp. Commercial 2 1 1
50%
1 —
404 Ryvu Therapeutics S.A. Commercial 2 0 0
0%
— 2
405 Salix Pharmaceuticals Inc. Commercial 2 0 0
0%
1 1
406 Sanofi Pasteur Commercial 2 0 0
0%
— 2
407 Santhera Pharmaceuticals (Schweiz) AG Commercial 2 0 0
0%
3 —
408 Santiago Dexeus Font Fundacio Privada Commercial 2 0 0
0%
— 2
409 Shire Human Genetic Therapies Inc. Commercial 2 0 0
0%
— 2
410 Sint Maartenskliniek Stichting Commercial 2 1 1
50%
— 1
411 Sintetica S.A. Commercial 2 2 2
100%
— —
412 Sk Life Science Inc. Commercial 2 2 2
100%
— —
413 Sling Therapeutics Inc. Commercial 2 0 0
0%
— 2
414 SocraTec R&D Concepts in Drug Research and Development GmbH Commercial 2 0 0
0%
— 2
415 Spruce Biosciences Inc. Commercial 2 2 2
100%
— —
416 St Antonius Hospital Academic 2 0 0
0%
— 2
417 St. Olavs Hospital HF Academic 2 1 1
50%
— 1
418 Stichting TRICALS Foundation Academic 2 1 1
50%
— 1
419 Substipharm Commercial 2 0 0
0%
2 —
420 Sumitomo Pharma Co. Ltd. Commercial 2 1 1
50%
— 1
421 Sydvestjysk Sygehus Commercial 2 0 1
0%
1 1
422 Tesaro Inc. Commercial 2 1 1
50%
— 1
423 Thoraxklinik Heidelberg gGmbH Academic 2 0 0
0%
— 2
424 Transcend Therapeutics Inc. Commercial 2 2 2
100%
— —
425 Transgene Commercial 2 0 0
0%
— 2
426 Trevena Inc. Commercial 2 2 2
100%
— —
427 Turku University Hospital Academic 2 0 0
0%
1 1
428 Ultragenyx Pharmaceutical Inc. Commercial 2 1 1
50%
— 1
429 United Therapeutics Corp. Commercial 2 0 0
0%
— 2
430 Universitaet Leipzig Commercial 2 1 1
50%
— 1
431 Universite Libre de Bruxelles Academic 2 1 1
50%
— 1
432 University College London Academic 2 1 1
50%
— 1
433 University Of Antwerp Academic 2 0 0
0%
1 1
434 University Of Minnesota Academic 2 2 2
100%
— —
435 University Of Oxford Academic 2 1 1
50%
— 1
436 Uniwersytet Jagiellonski Collegium Medicum Commercial 2 2 2
100%
— —
437 Uppsala Universitet Academic 2 0 0
0%
— 2
438 Upstream Bio Inc. Commercial 2 0 0
0%
— 2
439 Vall D Hebron Institute Of Oncology Academic 2 1 1
50%
1 —
440 Varsinais-Suomen hyvinvointialue Commercial 2 0 0
0%
1 1
441 VectivBio AG Commercial 2 1 1
50%
2 —
442 Ventus Therapeutics U.S. Inc. Commercial 2 0 0
0%
1 1
443 Verisfield Single Member S.A. Commercial 2 1 1
50%
1 —
444 Versantis AG Commercial 2 0 0
0%
— 2
445 Vestre Viken HF Commercial 2 0 0
0%
1 1
446 Viracta Therapeutics Inc. Commercial 2 0 0
0%
4 —
447 Vivet Therapeutics Commercial 2 0 1
0%
1 1
448 Win Medica Pharmaceutical S.A. Commercial 2 1 1
50%
— 1
449 Xentria Inc. Commercial 2 0 0
0%
— 2
450 Zealand University Hospital Academic 2 2 2
100%
— —

Data notes & methodology